Filana Therapeutics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value
Filana Therapeutics, Inc. (FLNA) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value of $35.16 per share for the 12-month period ending 2022-12-31, per its 10-K filed 2023-02-28.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue · last filed 2023-02-28
- Filana Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2022 was $35.16, a 46.59% decline from fiscal 2021.
- Filana Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2021 was $65.83, a 884.01% increase from fiscal 2020.
- Filana Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2020 was $6.69, a 318.13% increase from fiscal 2019.
- Filana Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2019 was $1.60, a 63.27% increase from fiscal 2018.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 12 month |
|---|---|
| 2022-12-31 | $35.16 10-K · filed 2023-02-28 |
| 2021-12-31 | $65.83 10-K · filed 2023-02-28 |
| 2020-12-31 | $6.69 10-K · filed 2023-02-28 |
| 2019-12-31 | $1.60 10-K · filed 2021-03-23 |
| 2018-12-31 | $0.98 10-K · filed 2020-03-26 |
| 2017-12-31 | $2.74 10-K · filed 2019-03-29 |
| 2016-12-31 | $1.60 10-K · filed 2018-02-06 |
| 2015-12-31 | $1.29 10-K · filed 2017-03-07 |
| 2014-12-31 | $2.32 10-K · filed 2017-03-07 |
| 2013-12-31 | $1.54 10-K · filed 2016-03-03 |
| 2012-12-31 | $1.70 10-K · filed 2015-02-18 |
| 2011-12-31 | $4.68 10-K · filed 2014-02-05 |
| 2010-12-31 | $2.23 10-K · filed 2013-02-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |
| BriaCell Therapeutics Corp. (BCTX) | $0.037B | ||
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B | |
| Seres Therapeutics, Inc. (MCRB) | United States | $0.036B | -3.45 |
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 |